Results 71 to 80 of about 19,267,272 (276)

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Randomized assessment of rapid endovascular treatment of ischemic stroke.

New England Journal of Medicine, 2015
BACKGROUND Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence despite alteplase treatment.
M. Goyal, A. Demchuk, B. Menon, M. Eesa, J. Rempel, J. Thornton, D. Roy, T. Jovin, Robert A. Willinsky, B. Sapkota, D. Dowlatshahi, D. Frei, N. Kamal, W. Montanera, A. Poppe, Karla J. Ryckborst, F. Silver, A. Shuaib, D. Tampieri, David J Williams, O. Bang, B. Baxter, P. Burns, H. Choe, J. Heo, C. Holmstedt, B. Jankowitz, M. Kelly, G. Linares, J. Mandzia, J. Shankar, S. Sohn, R. Swartz, P. Barber, S. Coutts, Eric E. Smith, W. Morrish, A. Weill, S. Subramaniam, A. Mitha, J. Wong, M. Lowerison, T. Sajobi, M. Hill   +43 more
semanticscholar   +1 more source

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Evaluating the Impact of Treating the Optimal Subgroup [PDF]

, 2016
Suppose we have a binary treatment used to influence an outcome. Given data from an observational or controlled study, we wish to determine whether or not there exists some subset of observed covariates in which the treatment is more effective than the ...
Luedtke, Alexander R., van der Laan, Mark J.   +1 more
core   +1 more source

Frequency and outcome of treatment in polycystic ovaries related infertility [PDF]

, 1969
Farzana Rizwan
openalex   +1 more source

Genomic correlates of clinical outcome in advanced prostate cancer

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been well-defined, but the association of genomic findings with patient clinical outcomes and with other characteristics including histology and ...
W. Abida, J. Cyrta, G. Heller, D. Prandi, J. Armenia, Ilsa M Coleman, M. Cieslik, M. Benelli, D. Robinson, E. V. Van Allen, A. Sboner, T. Fedrizzi, J. Mosquera, B. Robinson, N. De Sarkar, L. Kunju, S. Tomlins, Yi Mi Wu, Daniel Nava Rodrigues, M. Loda, A. Gopalan, V. Reuter, C. Pritchard, J. Mateo, D. Bianchini, S. Miranda, S. Carreira, P. Rescigno, J. Filipenko, J. Vinson, R. Montgomery, H. Beltran, E. Heath, H. Scher, P. Kantoff, M. Taplin, N. Schultz, J. Debono, F. Demichelis, P. Nelson, M. Rubin, A. Chinnaiyan, C. Sawyers   +42 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Sleep endoscopy with simulation bite for prediction of oral appliance treatment outcome

Journal of Sleep Research, 2013
The aim of this study was to assess the value of drug‐induced sleep endoscopy (DISE) using a custom‐made simulation bite in maximal comfortable protrusion (MCP) of the mandible, in the prediction of treatment outcome for obstructive sleep apnea (OSA ...
A. Vroegop, O. Vanderveken, M. Dieltjens, K. Wouters, V. Saldien, M. Braem, P. Heyning   +6 more
semanticscholar   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

Estimating treatment effectiveness with sample selection [PDF]

We consider a situation where treatment outcome is observed after two stages of selection; first of participation into the treatment, then in completion of the treatment. Estimates were obtained using two methods.
Bidisha Mandal, Laura G. Hill, Robert Rosenman, Vidhura Tennekoon   +3 more
core